(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/174775 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *A61P 35/04* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/CN2022/076554

(22) International Filing Date:
17 February 2022 (17.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202110189905.8 18 February 2021 (18.02.2021) CN
202110506596.2 10 May 2021 (10.05.2021) CN

(71) Applicant: **REMEGEN CO., LTD.** [CN/CN]; No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade Zone, Yantai, Shandong 264006 (CN).

(72) Inventors: **FANG, Jianmin**; ZHANG, Hui, No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade Zone, Yantai, Shandong 264006 (CN). **SU, Xiaohong**; ZHANG, Hui, No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade Zone, Yantai, Shandong 264006 (CN). **GUO, Xuguang**; ZHANG, Hui, No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade Zone, Yantai, Shandong 264006 (CN). **HE, Ruyi**; ZHANG, Hui, No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade Zone, Yantai, Shandong 264006 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER




FIG. 1

(57) Abstract: Provided is use of an antibody-drug conjugate targeting Her2 in the preparation of a medicine for treating breast cancer patients with liver metastasis or breast cancer patients without lung metastasis. Compared with a control drug group (lapatinib+capecitabine), the application of the antibody-drug conjugate provided in the treatment of breast cancer patients with liver metastasis and in the treatment of breast cancer patients without lung metastasis can significantly improve the survival time of the patients.

WO 2022/174775 A1